RJA
NVAX icon

Raymond James & Associates’s Novavax NVAX Stock Holding History

Raymond James & Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-140,969
Closed -$1.02M – 3911
2023
Q3 		$1.02M Buy
+140,969
New +$1.13M ﹤0.01% 2449
2022
Q3 		– Sell
-16,485
Closed -$848K – 4078
2022
Q2 		$848K Buy
+16,485
New +$854K ﹤0.01% 2554
2022
Q1 		– Sell
-3,322
Closed -$475K – 4233
2021
Q4 		$475K Sell
3,322
-644
-16% -$111K ﹤0.01% 3116
2021
Q3 		$822K Sell
3,966
-1,292
-25% -$285K ﹤0.01% 2711
2021
Q2 		$1.12M Sell
5,258
-1,960
-27% -$359K ﹤0.01% 2514
2021
Q1 		$1.31M Sell
7,218
-1,135
-14% -$226K ﹤0.01% 2309
2020
Q4 		$931K Sell
8,353
-506
-6% -$53.8K ﹤0.01% 2399
2020
Q3 		$960K Sell
8,859
-3,203
-27% -$390K ﹤0.01% 2205
2020
Q2 		$1M Sell
12,062
-2,930
-20% -$112K ﹤0.01% 2161
2020
Q1 		$204K Buy
14,992
+3,130
+26% +$26.5K ﹤0.01% 3030
2019
Q4 		$47K Buy
+11,862
New +$51.4K ﹤0.01% 3559
2019
Q2 		– Sell
-2,539
Closed -$28K – 3718
2019
Q1 		$28K Sell
2,539
-480
-16% -$15.2K ﹤0.01% 3513
2018
Q4 		$111K Hold
3,019
– – ﹤0.01% 3291
2018
Q3 		$114K Buy
3,019
+300
+11% +$8.45K ﹤0.01% 3418
2018
Q2 		$73K Sell
2,719
-618
-19% -$20.9K ﹤0.01% 3424
2018
Q1 		$140K Sell
3,337
-65
-2% -$2.61K ﹤0.01% 3222
2017
Q4 		$84K Sell
3,402
-117
-3% -$2.85K ﹤0.01% 3232
2017
Q3 		$80K Hold
3,519
– – ﹤0.01% 3202
2017
Q2 		$81K Buy
3,519
+200
+6% +$3.92K ﹤0.01% 3140
2017
Q1 		$85K Buy
3,319
+812
+32% +$22.3K ﹤0.01% 3090
2016
Q4 		$63K Buy
2,507
+953
+61% +$27.8K ﹤0.01% 3075
2016
Q3 		$65K Sell
1,554
-2,269
-59% -$293K ﹤0.01% 3060
2016
Q2 		$556K Buy
3,823
+537
+16% +$61.5K ﹤0.01% 2057
2016
Q1 		$339K Buy
3,286
+2,009
+157% +$216K ﹤0.01% 2252
2015
Q4 		$214K Buy
+1,277
New +$197K ﹤0.01% 2302

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James & Associates's NVAX Position: Q4 2023 in Review

Raymond James & Associates sold out of Novavax (NVAX) in Q4 2023, closing a stake of 140,969 shares — an estimated $1.02M sold.

Raymond James & Associates first reported a position in NVAX in Q4 2015 and held it in 25 quarters. The position peaked at $1.31M in Q1 2021. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

  • Raymond James & Associates reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 140,969 Novavax shares in Q4 2023, an estimated $1.02M.
  • Raymond James & Associates first reported a position in Novavax in Q4 2015 and held it in 25 quarters.
  • Raymond James & Associates's Novavax position peaked at $1.31M in Q1 2021.
  • 199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.